Project Grant K01HL188572
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $166K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Piscataway, NJ 08854, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Rutgers The State University of New Jersey, School of Nursing, $117,750 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic profiling and neurocognitive assessment to uncover stroke mechanisms in adults with sickle cell disease. The study quantifies neurodegeneration-associated and mitochondrial proteins in a cohort of 90 sex- and age-matched adults comprising 30 healthy controls, 30...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $232,836 on December 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomarkers of ischemic risk in adults with sickle cell disease using non-invasive quantitative neuroimaging methods. The research uses arterial spin labeling MRI and other quantitative imaging techniques to test hypotheses regarding cerebral oxygen utilization in patients with sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $171,488 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a nationwide examination of access to comprehensive care in sickle cell disease. The research uses national Medicaid insurance claims data to address two analytic aims. The first aim identifies three groups of people with sickle cell disease—those who do not receive care from a...
- The National Heart, Lung, and Blood Institute awarded Yale University $841,906 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, to conduct the SPIRIT-2 Study examining high-impact chronic pain in sickle cell disease. The study addresses three critical gaps in sickle cell disease pain management: identifying risk factors for sustained high-impact chronic pain and poor long-term outcomes; developing patient-centered endpoints to assess intervention efficacy from...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $168,351 on September 1, 2026, to develop and pilot-test a stigma reduction intervention targeting pain management in adults with sickle cell disease under the Cardiovascular Diseases Research program (CFDA 93.837). Dr. Lakeya McGill's K23 mentored career development award funds research, mentorship, and training to support her transition to independent investigator status. The project develops a patient-facing...
- The National Heart, Lung, and Blood Institute awarded Duke University $238,516 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct admixture mapping of genetic modifiers in sickle cell disease. The research leverages the National Heart, Lung, and Blood Institute's TOPMed program, which includes multiple cross-sectional adult sickle cell disease cohorts totaling more than 4,000 participants with whole genome sequencing data and extensive clinical...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $746,979 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of pain in sickle cell disease. The research uses transgenic mice with sickle cell disease to study how vaso-occlusive crises trigger severe pain. The project examines the role of lysophosphatidic acid (LPA), a pain mediator elevated during hypoxia-induced vaso-occlusion, and tests...
- The National Heart, Lung, and Blood Institute awarded $742,459 to Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient is conducting a comprehensive epidemiologic study evaluating treatment optimization among people with cystic fibrosis in the era of highly effective modulator therapy. The study leverages the Cystic Fibrosis Foundation Patient Registry linked to...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $834,899 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify inflammatory biosignatures that distinguish pain phenotypes in sickle cell disease. The research, titled "Inflammatory Biosignatures for the Identification of Sickle Cell Associated Pain Phenotypes (IBIS-CAP)," develops proteomic signatures composed of multiple biomarkers to characterize...